TriSalus Life Sciences Inc. (TLSI) - Total Assets
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) holds total assets worth $36.46 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TLSI total equity for net asset value and shareholders' equity analysis.
TriSalus Life Sciences Inc. - Total Assets Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.'s total assets have evolved over time, based on quarterly financial data.
TriSalus Life Sciences Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TriSalus Life Sciences Inc.'s total assets of $36.46 Million consist of 86.2% current assets and 13.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.6% |
| Accounts Receivable | $5.09 Million | 21.2% |
| Inventory | $4.05 Million | 16.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TLSI stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TriSalus Life Sciences Inc.'s current assets represent 86.2% of total assets in 2024, a decrease from 92.9% in 2021.
- Cash Position: Cash and equivalents constituted 35.6% of total assets in 2024, down from 80.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 21.2% of total assets.
TriSalus Life Sciences Inc. Competitors by Total Assets
Key competitors of TriSalus Life Sciences Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
TriSalus Life Sciences Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.05 | 2.40 | 0.57 |
| Quick Ratio | 2.75 | 2.00 | 0.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.42 Million | $13.89 Million | $-18.50K |
TriSalus Life Sciences Inc. - Advanced Valuation Insights
This section examines the relationship between TriSalus Life Sciences Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.29 |
| Latest Market Cap to Assets Ratio | 9.15 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | $23.97 Million |
| Market Capitalization | $219.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TriSalus Life Sciences Inc.'s assets at a significant premium (9.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: TriSalus Life Sciences Inc.'s assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for TriSalus Life Sciences Inc. (2021–2024)
The table below shows the annual total assets of TriSalus Life Sciences Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.97 Million | -2.55% |
| 2023-12-31 | $24.60 Million | +11.83% |
| 2022-12-31 | $22.00 Million | -41.87% |
| 2021-12-31 | $37.84 Million | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more